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Abstract 
Monolayer cloning studies were done to investiaate the hormonal 
dependence of the A7-DN human mammary tumor cell line and the growth 
inhibition of sequential and combination antiestrogen-antimetabolite 
therapy. The antiestrogen Tamoxifen (TAM) was found to inhibit colony 
growth in a dose-dependent manner. The sensitivity of these tumor 
cells to TAM was found to be independent of the insulin concentration 
in the medium, while the presence of insulin definitely increased the 
sensitivity of the cells to the growth inhibitory effects of 5-fluorouraci1 
(FUra). 
The interactions of TAM with the antimetabolites methotrexate (MTX), 
FUra, and combined MTX-FUra (MF) were studied under conditions of 
sequential and combination treatment. For sequential experiments, TAM 
treatment is followed by washing out the drua and adding fresh medium 
containinci estrogen before antimetabolite treatments. For combination 
therapy experiments, TAM administration precedes antimetabolite treat¬ 
ment, without intervening washing or addition of fresh media. TAM 
does not clearly interact with MTX synergistically, but at high doses 
of TAM, sequential TAM-MTX appears superior to combination treatment 
in growth inhibitory ability. On the other hand, high doses of TAM 
in combination with FUra are more cytotoxic than sequential TAM-FUra. 
Finally, TAM does enhance the cytotoxicity of MF synergistically if 
given in sequential fashion. The biochemical basis for this interaction 
may reside in the ability of TAM to effect cell cycle synchronization 
of the tumor cells. 
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I. introduction 
A. Breast Cancer: Clinical Significance 
Breast cancer, which affects approximately one out of eleven American 
women, represents a significant health problem in the United States (1). 
Surgery and radiation therapy are the dominant modes of therapy for the 
primary lesion; however, recurrence rates are hiah. Because disseminated 
disease is currently always fatal, improved methods of combination 
chemotherapy are needed (2). 
The invasion of axillary lymph nodes by tumor cells at the time of 
mastectomy offers some prognostic insight into the development of re¬ 
current disease. Twenty-one percent of patients with negative axillary 
nodes at surgery develop recurrent disease within 5 years, and 70% 
of patients with no axillary node involvement survive 10 years. Pa¬ 
tients with 1 to 3 positive nodes develop recurrent disease within 5 
years at a rate of 53%, while patients with more than 4 nodes involved 
have an 80% recurrence rate. Of all patients with axillary node in¬ 
volvement, less than 30% survive over 10 years (2). These figures 
certainly demonstrate the problem of recurrent disease and have led 
to attempts to reduce recurrence by the use of adjuvant chemotherapy 
in women with primary breast cancer and positive axillary nodes (3). 
Currently, methotrexate (MTX) and 5-fluorouraci1 (FUra) are among 
the most commonly used drugs in the treatment of metastatic breast 
carcinoma. Individual response rates are on the order of 20 to 30%, 
and when used in combination with other agents, response rates of 50 to 
60% may be achieved (5). In vitro studies have shown that synergistic 
4 
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inhibition of the clonal growth of an estrogen-sensitive human breast 
tumor cell line results when MTX exposure precedes the administration of 
FLIra (4). Preliminary clinical studies suggest that this sequence is 
highly effective in the treatment of advanced breast cancer (5). 
Tamoxifen (TAM) is a non-steroidal antiestrooen and has been used in the 
hormonal therapy of breast carcinomas containing estroaen receptors. 
In one study 22% of patients showed definite tumor regression in re¬ 
sponse to TAM therapy while 37% showed improvement with variable tumor 
regression (6). Investigation of the effects of combining TAM therapy 
with anti metabolite therapy such as sequential MTX-FUra may provide 
an improved mode of treatment of metastatic breast cancer. 
B. Endocrinology of Breast Cancer 
Estrogen receptors may be detected in 50 to 65% of all breast cancers 
(7). Studies of human mammary cell lines have generally failed to show 
an absolute dependence of the cells on estrogen for orowth, but maximum 
growth is only obtained when appropriate concentrations of the hormone 
are present in the growth medium (8). Estrogen enters cells and binds 
to cytoplasmic estrogen receptors (ER). The resultina complex then enters 
the nucleus by a translocation process and binds to nuclear chromatin, by 
which it may direct the synthesis of specific ribonucleic acid (RNA) 
molecules (8,9). The loss of estrogen-receptor complex from the nucleus 
is referred to as processing. This processing step correlates with 
progesterone receptor (PgR) induction in the MCF-7 mammary carcinoma 
cell line, providing good evidence that stimulation of synthesis 
of PgR is one of the effects of estradiol on the cell (7). Other 
markers of estrogen action on cells include the induction of a secreted 
4 
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glycoprotein in mammary carcinoma cell lines by estradiol (10). 
The 47-DN human mammary carcinoma cell line is an appropriate 
system for the study of the endocrinology of breast cancer. The cell 
line, established from the oleural effusion of a patient with breast 
cancer, contains estrogen receptors, which are largely localized to the 
nucleus (11,12). The cells also show the induction of the aforemen¬ 
tioned secreted glycoprotein upon exposure to estradiol (10). The 
growth of the 47-DN line is also sensitive to the effects of insulin 
(11), and this property aids in the usefulness of this system as a 
biological model of breast carcinoma in that Cohen and Hi If have re¬ 
ported that a certain group of carcinogen-induced mammary tumors in 
rats may be considered insulin dependent (13). 
C. Tamoxifen 
Harper and Walpole first showed the anti-estrogenic activity of TAM 
in evaluating a series of substituted triphenylethylenes (14). The 
structure of TAM is shown in Figure 1. This compound was found to 
/<3Z2> 
\ CH2CH3 
Tamoxifen 
counter the effects of estrogen on the vaginal epithelium and uteri of 
rats. It also prevents ovulation and terminates early pregnancy. 
The drug was later used in the hormonal therapy of breast cancer 
as an alternative to the more drastic measures of oophorectomy and 
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adrenalectomy. Cole et a]_. showed definite tumor response in about 
22% of patients treated with TAM (6). These patients received either 
1 or 2 lOmq tablets per day. Ward's early studies showed definite re¬ 
sponses in 36% of patients treated with 10ma of TAM twice daily and 
partial resDonses in an additional 24%. In patients who were oiven 
20mq TAM twice daily the definite response rate was 40%, and the par¬ 
tial rate 37%. 
Numerous studies have been undertaken to determine the mode of 
the tumor growth inhibitory action of TAM. Studies of the MCF-7 cell 
line have shown that both TAM and nafoxidine (NAF) bind estrogen receptor 
and translocate them to the nucleus. While NAF results in no processing 
of the receptors, TAM leads to processing on the order of 30 to 50% 
of that seen with estradiol (8). Low doses of TAM (0.01 to 0.luM) have 
an estrogenic effect, which may be measured by PqR induction. On the 
other hand higher doses (lyM) lead to the suppression of PgR levels 
below control levels and are accompanied by inhibition of cell growth 
and eventual cell death (8,16). Antiestrogens have also been shown to 
inhibit deoxyribonucleic acid (DNA) polymerase activity (17) in the 
MCF-7 cell line. The presence of O.lyM 17-e-estradiol did not affect 
growth or DNA polymerase activity, and over a wide range of doses 
(0.0001 to lOOOmM) estradiol had no significant effect on the activity 
of DNA polymerase. Both NAF and TAM reduced the activity of DNA poly¬ 
merase when present in concentrations of lyM; this reduction in activity 
could be reversed by the addition of estradiol. TAM was somewhat less 
effective than NAF in reducing DNA polymerase activity, and its effects 
could be reversed by lower doses of estradiol than for NAF inhibition. 
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Other workers have shown inhibition of macromolecular DNA synthesis 
by O.lyM TAM in the MCF-7 line which could be reversed by estradiol 
administration (18). 
Binding studies have yielded confusing information concerning the 
important binding sites of TAM in cells and their relationship to arowth 
inhibitory effects. While the effects of TAM on cells and the ability 
of estradiol to prevent these effects suggests an estroaen receotor- 
mediated action for TAM, the work of some investigators has suggested 
that TAM is predominantly bound by a site distinct from the classical 
estrogen receptor in human breast cancer. Sutherland and Murphy used 
human mammary carcinoma biopsies to investigate comoetitive binding be¬ 
tween TAM and estradiol (19). They found the presence of a saturable, 
high affinity TAM binding site in tumors which were shown to contain 
estrogen receptors but not in those which had no detectable receDtor 
levels. While TAM is bound predominantly to its own site, it is able 
to inhibit the binding of 17-e-estradiol to its receptor with a relative 
binding affinity of 0.87 + 0.35%. However, estradiol was unable to inhi¬ 
bit the binding of TAM to its binding site. The authors estimated 
that less than 5% of administered TAM is bound to the estrogen recep¬ 
tor. Sutherland et al. also reported the presence of this TAM binding 
site distinct from the estrogen receptor in the MCF-7 line and suggest 
that TAM is bound to both the ER and its own site (20). 
Other studies only add to the complexity of the issue. The competitive 
binding studies of Nicholson et a_K did show the ability of estradiol 
to inhibit TAM binding (21), but those investigators used lower ligand 
concentrations which may have led to the observation of greater TAM 
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binding to ER than seen in the studies of Sutherland and Murphy (19). 
Nevertheless, the estrogen receptor must have some relevance to the 
action of TAM. Butler et aj_. determined the effects of insulin on the 
sensitivity of MCF-7 to estrogen and antiestrogen (22). The addition 
of insulin to the growth medium decreases sensitivity to estrogen as 
measured by a decrease in production of plasminogen activator, a marker 
of estrogenic effects. The presence of insulin also decreased the sen¬ 
sitivity of the cells to TAM. The authors explain these findinqs by the 
ability of insulin to lower the number of estrogen binding sites from 
62,000 + 9,700 to 21,000 + 4,700. The fact that TAM is more effective 
when there is an increased number of estrogen receptors present suaaests 
that the growth inhibitory potential of TAM is due to some active in¬ 
hibitory role of a TAM-ER complex, rather than mere competition between 
TAM and estradiol for ER binding sites. 
TAM is able to inhibit the secreted glycoprotein induced by estrogen 
in the MCF-7 line (10), and this also supports some involvement of TAM 
in estrogen receptor interactions. Still, the presence of ER does not 
necessarily imply sensitivity to TAM. A cell line has been derived 
from MCF-7 which is resistant to the growth inhibitory effects of TAM 
but which still contains estrogen receptors (23). The effect of estradiol 
on cell growth is slightly weaker than in the TAM-sensitive MCF-7, but 
estrogen is still able to induce PgR in these cells, indicating the pre¬ 
sence of an intact estrogen receptor mechanism. Clinical studies indicate 
that only 50 to 70% of patients with tumors containing estrogen receptors 
respond to anti hormonal therapy (24), also indicating that the presence 
of ER is not an absolute predictor of TAM efficacy. 
\ 
10 
Human studies have shown an effect of TAM on estrogen receptors. 
Waseda et a]_. studied tumor specimens from patients who had been treated 
with TAM and found that while short term TAM administration could in¬ 
crease levels of nuclear estrogen receptor, long term administration led 
to a decrease in nuclear estrogen receptor content and a decrease in 
levels of PgR (25). 
All of the above studies are not inconsistent with a model in which 
intracellular TAM binds to at least two sites. By bindinq to the clas¬ 
sical estrogen receptor and preventing complete processing and also 
possibly binding to chromatin and actively inhibiting cellular processes, 
TAM clearly exerts an antiestrogenic effect. TAM may also bind to another 
specific site, which may or may not be involved in its actions on the 
cell. This site may in fact be analogous to the Tyoe II sites reported 
in uterine cytosol (26). These sites may have a much lower binding 
affinity for estradiol and a higher affinity for TAM than the classical 
estrogen binding sites, and estradiol would thus be ineffective in 
inhibiting the binding of TAM. Clark et al_. suggest that these Type 
II sites may serve to retain estrogen within cells, thus providing 
the classical sites with an estrogen-rich environment (26). This site 
could also bind TAM in large quantities, only a small but sufficient 
portion of which might be interacting with and altering the classical 
estrogen receDtor mechanism. 
Regardless of its mechanism of action, TAM is clearly able to inhibit 
DNA synthesis in MCF-7 (18). This effect may be reversed by the addition 
of estradiol to the medium. Recovery of the cells is accompanied by a 
rise in thymidine incorporation rates to levels above control values 
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during the early phase of estradiol rescue of the cells. This observa¬ 
tion suggests that a greater proportion of the cells are entering the 
DNA synthetic phase of the cell cycle, and so TAM has effected a syn¬ 
chronization of the tumor cell population. Therefore, TAM may have 
some role as a synchronizing agent in possible combination chemotherapy 
regimens for breast cancer. 
2 
Pharmacokinetic studies suggest that single daily doses of 20mg/m 
of TAM are sufficient to maintain blood levels in the therapeutic ranae 
(>_150 mg/ml) after 8 weeks of treatment (2,7). This blood level is 
equivalent to 0.55yM. Peak concentrations are found in blood 4 to 7 
hours after oral administration. TAM concentration decreases in a 
biphasic fashion with an initial half life of 7 to 14 hrs, followed 
by a terminal half life longer than 7 days. TAM is metabolized bv 
hydroxylation and conjugation; most metabolites are excreted in the 
stool (2,8). Side effects of TAM are rare and usually tolerable in¬ 
cluding hot flashes, nausea, vomiting, tumor pain and headaches most 
cotrmonly (6,15). 
D. Methotrexate 
Methotrexate (MTX) exerts antitumor action by virtue of its anti- 
metabolic effects as an analogue of folic acid (28). MTX produced the 
first remissions in leukemia and is useful in choriocarcinoma, acute 
lymphocytic leukemia, and solid tumors of the breast, ovary, head and 
neck, and lung. The structure of MTX is given in Figure 2. 
MTX enters cells by a carrier-mediated process and exerts its cyto- 
cidal effect via tight binding and inhibition of the enzyme dihydrofolate 
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reductase. Enzyme blockade is only achieved if free intracellular MTX 
is in excess to the target enzyme. This inhibition prevents regeneration 
of reduced folic acids, and depletion of tetrahydrofolic acid pools 
results as reduced folates are oxidized in the reaction catalyzed by 
thymidylate synthetase (Figure 3). 
Figure 2. Methotrexate 
thymidylate synthetase 
Figure 3. The enzymatic conversion of deoxyuridylate to deoxythymidylate. 
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This can have effects on a number of biosynthetic pathways in nucleic 
acid biosynthesis, as shown in Figure 4. The purine biosynthetic 
pathway is blocked at the step involving conversion of glycinanide phos- 
phoribose to formylglycinamide phorphoribose. The subsequent accumu¬ 
lation of phosphoribosyl pyroDhosphate (PRPP) can modulate the pyrimidine 
pathway (29). 
Cytocidal effects of MTX are dependent on the cells' enterina the 
DNA synthetic phase of the cell cycle, for pyrimidine biosynthesis must 
be occurring to deplete tetrahydrofolate pools. In order to achieve 
high intracellular concentrations of MTX, high doses are occasionally 
given to patients. Because of potential serious toxic effects of 
these doses of MTX, the patients are then "rescued" by the administration 
of leucovorin, or 5-formyltetrahydrofolate. This serves to replenish 
depleted reduced folate pools and restore normal cell metabolism. 
The toxicity of MTX is self-limiting. Because of the wide uses of 
folate in cell metabolism, MTX inhibits RNA and protein synthetic me¬ 
chanisms, thus slowing the entry of cells into the DNA synthetic phase. 
The cells therefore become less sensitive to the lethal effects of 
MTX. Resistance to MTX is also found in some cells and may occur by 
one of three mechanisms. Impaired transport of MTX into cells leads 
to the inability to achieve the necessary high intracellular concen¬ 
tration of MTX. A second mechanism for resistance involves the pos¬ 
session of a form of the enzyme dihydrofolate reductase with a reduced 
affinity for MTX. A third means is from increased levels of dihydrofolate 
reductase which may be achieved by enzyme induction. 
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Pyrimidine Synthesis Purine Syntnet'S 
ATP-♦ RNA --- GTP 
Figure 4. Nucleic acid biosynthetic pathways. 
While highest response rates to MTX have been observed in rapidly 
growing tumors, MTX also has beneficial effects in a number of slowly 
growing solid neoplasms. MTX also has been used in the adjuvant treat¬ 
ment of cancer. The rationale for this is that after surgical removal of 
the primary lesion, MTX is highly active against small tumor foci with 
a high growth fraction. Furthermore, the patients are more capable of 
tolerating drug-related toxicity when they are least debilitated by the tumor. 
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(29). As was mentioned above, individual response rates of patients 
with advanced breast cancer are 20 to 30% (5). MTX adversely affects the 
intestinal tract, bone marrow, kidneys and liver; intrathecal adminis¬ 
tration may cause neurotoxicity. 
E. 5-F1uorouraci1 
5-Fluorouraci1 (FUra) (Figure 5) must be metabolized by cells for 
cytotoxic effects to be realized (31). Anabolic mechanisms (Figure 6) 
may convert FUra into fluorouridine (FUrd), fluorodeoxyuridine (FdUrd), 
or fluorouridylate (FUMP). Fluorodeoxyuridylate (FdUMP) may be formed 
either by phosphorylation of FdUrd or from FUMP via FUDP and FdUDP. FdUMP 
represents one of the major cytotoxic metabolite of FUra, for it inhibits 
the enzyme thymidylate synthetase in the presence of 5,10-methylenetetra- 
hydrofolic acid. The three species are necessary for a stable ternary 
inhibitory complex. This inhibition prevents the formation of deoxy- 
thymidylate and thus DNA, so that this means of FUra toxicity is depen¬ 
dent on the cells entering DNA synthesis, as for MTX. Cell death has also 
been associated with chromosomal breaks (32). 
There exists another pathway for FUra cytotoxicity however, and this 
involves the conversion of FUMP to FUDP and then FUTP and its incorpora¬ 
tion into various RNA species. The product of such "fraudalent" RNA 
molecules may lead to miscoding during translation of messenger RNA (mRNA) 
into protein or to alteration in normal post-transcriptional processing 
and maturation of mRNA. The relative importance of these two major 
mechanisms of cytotoxicity of FUra remains a point of controversy. The 
contribution of each probably depends heavily on the metabolic states of 
the cells involved and may be manipulated pharmacoloaically. 
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Figure 5. 5-F1 uorouraci 1. 
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Figure 6. Pathways of FUra metabolism 
Key: 1. Thymidine, deoxyuridine phosphorylase x Degradation products 
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10. Thymidylate synthetase 
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Because gastrointestinal absorption of the drug is unpredictable 
and incomplete, FUra is usually administered intravenously. The clinical 
uses of FUra include palliative treatment of carcinomas of the breast, 
gastrointestinal tract, liver, ovary, cervix, urinary bladder, prostate, 
pancreas and oropharyngeal areas. FUra is cytotoxic to bone marrow and 
gastrointestinal epithelium, so that clinical toxicity is manifested by 
anorexia, nausea, vomiting, diarrhea, stomatitis, and leukopenia. Re¬ 
sistance to FUra may develop and may be due to a decrease in uridine 
kinase activity, a decrease in phosphoribosyltransferase activity, or 
the presence of a resistant form of thymidylate synthetase (28,31,32). 
F. Methotrexate-5-Fluorouraci1 Interactions 
The interactions of MTX and FUra have been studied extensively. 
If FUra exerts its primary cytocidal effect via its inhibition of thy¬ 
midylate synthetase, then the addition of MTX should antagonize its 
effects. The MTX-induced depletion of tetrahydrofolic acid pools 
theoretically prevents the formation of the ternary complex of thy¬ 
midylate synthetase, FdUMP, and 5,10-methylenetetrahydrofolate. It 
appears that MTX, as an analogue of folic acid, may participate in the 
forming of such a ternary complex, but such a complex does not seem 
to be found to any great extent in experimental systems (29). Experi¬ 
mentally, drug synergism is observed when MTX administration precedes 
FUra (4,29,33). Since MTX probably antagonizes the FdUMP-mediated 
cytotoxic effect of FUra, a search for another mechanism for this 
synergism was undertaken. 
FUra may also exert a toxic effect through its incorporation into 
RNA,and MTX enhancement of this incorporation may explain the syner- 
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gism. Cadman et_ jil . showed that MTX treatment of the murine leukemia 
cells L1210 leads to increased PRPP pools which can cause increased for¬ 
mation of intracellular FUra nucleotides. PRPP is used in purine bio¬ 
synthesis, so that MTX-mediated inhibition of the purine biosynthetic 
pathway leads to a decreased utilization of PRPP and a subsequent ac¬ 
cumulation of PRPP within the cell. These PRPP molecules may serve 
to form FUra nucleotides, including both FUTP and FdUMP. Because MTX 
antagonizes the FdUMP-mediated cytotoxic effect, the observed synergism 
between MTX and FUra is likely due to the increased formation of FUTP 
and its incorporation into RNA. The mechanisms for cytotoxicity as 
a result of this fraudulant RNA were discussed above. 
In the human breast carcinoma cell line, 47-DN, maximal cytotoxicity 
is present when FUra is administered in the last 6 hours of a 24-hour MTX 
treatment (4). MF has also demonstrated potential benefit in the clinical 
treatment of advanced breast cancer (5). 
G. Antiestrogen-Antimetabolite Interactions 
Further enhancement of the antitumor effects in breast cancer 
of these antimetabolites used either singly or in combination may be 
achieved via combining them with hormonal therapy, particularly TAM. 
Several clinical studies have been undertaken to determine the efficacy 
of combining the modalities of hormonal and chemotherapy of breast 
cancer. One of these compared the use of either TAM, L-phenylalanine 
mustard, and FUra or L-phenylalanine mustard and FUra alone in the adjuvant 
chemotherapy of patients with one or more positive axillary nodes (3). 
Patients were given TAM twice daily for the 2 years of the protocol. 
L-phenylalanine mustard and FUra were administered daily on the first 5 
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days of a 6-week cycle. Overall, there was significantly increased 
disease-free survival of those patients treated with TAM plus chemo¬ 
therapy. The main group which benefited were the patients >49 years 
old with high ER levels. In patients <49 years old, the only group 
receiving benefit from TAM were those with 4 or more positive nodes 
and high ER levels. The administration of TAM produced no additional 
toxicity other than an increase in the incidence of hot flashes. 
Another study reporting benefit from the addition of TAM to chemo¬ 
therapeutic regimens in the adjuvant treatment of breast cancer is that 
of Hubay £t aj_. (34). This group compared the use of cyclonhosDhamide 
(Cytoxan), MTX, and FUra (CMF), and CMF plus TAM (CMFT). Treatment 
was given according to 28-day cycles, in which cytoxan was administered 
on days 1 through 14, while MTX and FUra were given on days 1 and 8. 
Patients received TAM daily for one year. Patient response depended 
upon ER status; CMFT treatment was significantly more effective in de¬ 
laying recurrence than CMF alone in patients with ER-containing tumors, 
regardless of menopausal status. 
One group has reported preliminary results on the use of TAM and 
chemotherapy in the treatment of advanced breast cancer (35). The drug 
regimen involved TAM treatment for 10 days, followed by estrogen therapy 
for 4 days, on the last day of which patients received MTX-FU 
treatment. The rationale for this study involves the concept of 
estrogen rescue and stimulation of ER-containine breast cancer cells, 
which should be sensitive to the effects of seguential MTX-FU. Only 
9 patients have been evaluated, and 7 reSDonded to the theraoy. In 
fact 5 attained a complete remission. While this study obviously can 
only offer preliminary results, the conclusion to be obtained from all 
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these clinical studies is that there is some rational basis for com¬ 
bining hormonal and chemotherapeutic regimens in the treatment of 
breast cancer. 
How might TAM interact with the druas discussed above? In a 
"combination" regimen, TAM could be given and another agent or aaents 
could be given either simultaneously or at some later time when TAM 
was still present. "Sequential" therapy would involve TAM adminis¬ 
tration followed by an "estrogen rescue" (18,35), after which the 
antimetabolites would be given. 
A priori, the combination of TAM and an S-phase specific agent 
such as MTX might be expected to be antagonistic, since TAM inhibits 
DNA synthesis (18). Furthermore, the synergism of MF is dependent 
on DNA synthesis and TAM-dependent inhibition of this process might 
decrease the cytotoxicity of the antimetabolites. The effects of com¬ 
bining TAM and FUra are certainly less predictable, because FUra's 
cytotoxic actions involve at least 2 mechanisms, only one of which is 
dependent on cells' synthesizing DNA. 
The sequential therapy takes advantage of the fact that TAM followed 
by estrogen rescue may result in some degree of cell cycle synchronization 
of the tumor cells (18). Cell cycle synchronization results in an in¬ 
creased proportion of cells entering S-phase following rescue. An in¬ 
creased proportion of cells in S-phase does increase cell killing by 
S-phase specific agents (36), so that TAM-induced synchronization of 
breast cancer cells may increase MTX and MTX-FUra cytotoxicity. Syn¬ 
chronization of cells would not necessarily increase the cytotoxicity of 
FUra, because its effects are not limited to cells which are actively 
synthesizing DNA. 
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Cytotoxicity of MTX has been shown to increase with proliferative rate 
of tumors (37), and several investigators have shown than tumors with 
high growth fractions (which may occur during rebound from a cell cycle 
block) respond to cycle-specific therapy better than those with a low 
growth fraction (38,39,40,41). Steel has identified one problem in the 
application of cell cycle synchronization to therapeutic use, and that 
is that tumor synchronization and increased tumor cell kill will be 
accompanied by normal host tissue synchronization and increased normal 
cell kill and increased host toxicity, with no subsequent improvement 
in therapeutic index (42). This problem may be circumvented with the 
use of an agent such as TAM, whose synchronizing effects should only 
be observed in cells containing estrogen receptors. Host toxicity 
should not then be increased to any great extent. 
H. Objectives 
In vitro studies may answer many of the questions concerning TAM and 
antinetabolite interactions. The use of the human breast cancer cell 
line, 47-DN, provides a suitable experimental system for studying 
this problem. This work proDoses to evaluate the growth inhibitory 
effects of TAM alone in the 47-DN cell line and also the hormonal de¬ 
pendence of TAM cytotoxicity. The hormonal dependence of FUra effects 
on the cells is also examined. Finally,the interactions of TAM and 
MTX,FUra,and MF in both combination and seauential fashion are evaluated 
according to ability to inhibit colony growth of 47-DN. 
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II. Materials and Methods 
A. Cells 
The 47-DN breast tumor cell line is a well-characterized, continuously 
growing monolayer cell line (11), which has a doubling time of 26 hours 
under our culture conditions. Cells were maintained in Roswell Park Memorial 
Institute Medium 1640 (Grand Island Biological Co. (GIBCO), Grand Island, 
NY) supplemented with 10% of a 1:1 mixture of fetal bovine serum and 
newborn calf serum (GIBCO). Stocks were grown in media containino 0.2 
IU/ml insulin (Eli Lilly Co., Indianapolis, IN) and InM estradiol (Sigma 
Chemical Co., St. Louis, MO). Medium changes made for certain experiments 
are described under "Results." The estradiol content of serum was measured 
and found to be less than lOOpM. Stocks were passaged weekly using a 
trypsin (0.05%)-EDTA (0.02%) solution and viaorous Dipettina to obtain 
2 
a suspension of >90% single cells. Cells were grown in 75 cm sterile 
plastic culture flasks (Costar Data Packaging, Cambridge, MA) with 25ml 
medium in 5% CO2 incubators at 37°C. All cell counts were performed 
on a Coulter Model ZBI Counter (Hialeah, FL). 
B. Drugs 
TAM, obtained from ICI Americas, Inc. (Wilmington, DL), was dissolved 
in absolute ethanol and kept in a 0.01M stock solution. All dilutions 
were made with ethanol, and control flasks in TAM experiments received 
a volume of ethanol eguivalent to that received by TAM treated flasks. 
Solutions of MTX (Sigma), were made in sterile phosphate buffered saline 
(PBS) from 0.001 M stock solutions. FUra (Sigma) was also dissolved in 
PBS to give a stock solution of 0.01 M, from which PBS dilutions were made. 
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C. Monolayer Colony Growth Experiments 
Stock cultures were washed with PBS, and cells were removed by 
trypsinization and vigorous pipetting. 30,000 to 40,000 cells were 
seeded into each flask with 25ml of medium and grown in 5% C0>2 in¬ 
cubators at 37°C. In some experiments involving multiple drug treat¬ 
ments, >40,000 cells were seeded in each flask; final colony counts 
were corrected accordingly. On the 3rd to 4th day after seeding, when 
colonies consisted of 4 to 32 cells, drug treatments were begun. These 
small colonies are representative of the micrometastases thought to be 
present in human malignancies. Up to 90% of cells can be killed with¬ 
out a change in the number of colonies which grow, so colony growth 
inhibition represents quite significant cell kill (43). Volumes of 
either 25yl or 250p 1 of drug solution were added to flasks to obtain 
appropriate final concentrations in the medium. Drug treatments were 
terminated by pouring off of medium, washing with PBS, and adding 
fresh medium. TAM was given for variable times, MTX for 24 hours, 
and FUra for 6 hours. MF treatments involved administerina FUra for 
the last 6 hours of a 24-hour MTX exposure. In some experiments, 
as noted in "Results," just before drug treatment, the medium was 
changed to RPMI 1640 + 0.2 IU/ml insulin + 1.0 nM estradiol +10% 
dialyzed fetal bovine serum. After all drug treatments were 
terminated, cells were allowed to grow until control flasks reached 
2 
a density of approximately 1000 cells per 2000 mm . At this time, 
usually about 10 days after seeding, the medium was removed from all 
flasks and cells were washed with PBS and stained with a methanol- 
crystal violet (2.5%) solution. Colonies were enumerated using an 
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automated colony counter (Biotran II; New Brunswick Scientific Co., 
Inc., Edison, NJ). The sensitivity of the counter was set to obtain 
2 
maximum counts from control flasks in counting fields of 2000 mm . 
Three fields were counted per flask, and with at least 2 flasks per 
experimental condition, at least 6 data points were obtained from 
which a standard deviation could be calculated. Comparison of manual 
counting using an inverted microscoDe and colony counts from the 
counter showed that automated counts were approximately one half of 
manual counts. This means that the true cloning efficiency of the 
system is approximately 20%, while the effective efficiency is approx 
2 
imately 10%, assuming a count of 1000 colonies per 2000 mm field 
of a 75 cm^ flask seeded with 40,000 cells. 
D. Data Analysis 
For each growth condition, at least 2 simultaneous experiments 
were done, so that 6 data points were obtained from which means and 
standard deviations could be calculated. In the FUra sensitivity 
studies, an analysis of variance between the means obtained from two 
experiments is performed. In the combination drug studies, many 
more experiments were done, and because of the great deal of varia¬ 
bility among experiments, an ICE value (index of combined treatment 
effect) is calculated. Because each experiment done with a set of 
flasks seeded at one time involves both single and multiple drug 
treatments, it is possible to determine if the observed growth is 
greater or less than that expected if additive effects were occurring 
For example, for an experiment with MTX, FUra and MF, the ICE for MF 
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is equivalent to % control growth for MF/ (% control growth for 
MTX) (% control growth for FUra). An ICE>1 implies that the drugs 
are interacting antagonistically, while ICE values <1 indicate drua 
synergism. An ICE =1 indicates purely additive effects. Mean ICE 
values + S.D. are calculated from at least 6 data points and a two- 
tailed t test is performed to determine significant difference from 
1.0. In an experiment performed in dialyzed serum, ratios of % 
control growth after multiplied drug treatments to % control Growth 
in TAM only are calculated, and sequential and combination type 
schedules are compared using a two-tailed t test. 
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III. Results 
A. Tamoxifen Sensitivity of 47-DN 
To determine the ability of TAM to inhibit colony qrowth of 47-DN, 
cells were treated with concentrations of TAM ranging from O.OlyM 
to 10yM at exposure times ranging from 1 hour tc continuous exposure. 
Figure 7 shows the clonal growth of these treated cells. In this 
experiment the medium contained 2 IU insulin/ml. Drug or ethanol 
treatments involved the addition of 25yl to each flask. Growth in¬ 
hibition is clearly seen beginning with a 24-hour exposure to 10uM 
TAM. 10yM TAM for 48 hours leads to approximately 30% growth, while 
a 
O.OlpM TAM has little effect on 47-DN. 
Cells which were growing in RPMI 1640 + InM estradiol and several 
insulin concentrations were exposed to various doses of TAM for 48 hours 
and colony growth determined. Figure 8 shows that there is no real 
difference in sensitivity of the various groups of cells. 10pM 
TAM produces from 50 to 60% inhibitionof colony growth of cells grown 
in all media. 
B. Sensitivity of 47-DN to FUra 
A dose-response relationship for FUra treatment of 47-DN was es¬ 
tablished by treating cells grown in 4 different types of media. All 
were grown in RPMI 1640, with either one or both or neither of InM 
estradiol or 2 IU/ml insulin. Figure 9 shows that a 6-hour exposure to 
5yM FUra produces greater inhibition of growth when insulin is present 
than when no exogenous insulin is added to the medium. This effect is 
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Figure 7. Clonal growth of Tamoxifen treated 47-DN. 
Cells were exposed to varying concentrations of TAM for varying times 
beginning on the 3rd to 4th day after seeding. Growth was assayed as 
described in methods and expressed as mean number of colonies per 2000 
? 
mm area + 1 standard deviation. Each condition represents 6 data points 
obtained from two separate, simultaneous experiments. 
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Fiqure 9. 47-DN sensitivity of FUra ± Insulin (I), ± Estradiol (E). 
Cells were grown in RPMI 1640 + 1 nM estradiol + 4 different concen¬ 
trations of insulin (0, 0.02, 0.2, 2 IU/ml) and exposed to varying con¬ 
centrations of 48 hour TAM. Growth is presented as mean % control growth 
+ range of mean value for two separate experiments, each involving 
duplicate flasks. 
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Table 1 
INSULIN DEPENDENT SENSITIVITY OF 47-DN TO FUra 
Mean % Clonal Growth 
yM FUra (6hr) -insulin__+ insulin p* 
0.5 100 84 >.10 
1.0 97 70 >.10 
5.0 93 51 <.05 
10.0 40 25 >.10 
one-way analysis of variance 
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Figure8 . Effect of Insulin on 47-DN sensitivity to Tamoxifen. 
Cells were grown in RPMI 1640 sith varying combinations of InM estradiol 
and 2 IU/ml insulin and exposed to 6 hour FUra. Clonal growth is expressed 
as percentage of control growth + S.D. determined from 6 data points from 
duplicate, simultaneous experiments 
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independent of estradiol content of the medium. Table 1 shows the mean 
results of two such experiments, one of which is presented graphically in 
Figure 9. The other experiment was identical except that 0.2 IU/ml in¬ 
sulin was used. Clearly, the presence of insulin significantly increases 
the sensitivity of 47-DN to the growth inhibitory effect of FUra. 
C. TAM-Antimetabolite Interactions 
A number of experiments were undertaken to examine the interactions 
of TAM, MTX, FUra, and MF. Doses of 0.5yM and 5yM were used for MTX 
and FUra, respectively, on the basis of previous work (44), and cells 
were exposed for 48 hours to either O.OlyM TAM or 1 OpM TAM. In 
"combination" experiments, MTX is given during the last 24 hours 
of the 48 - hour TAM exposure and FUra is given in the last 6 hours. 
In "sequential" experiments TAM is administered for 48 hours, 
after which the drug is washed out, medium replaced and antimetabolite 
treatments begun immediately in the case of MTX, or 18 hours later, 
in the case of FUra. Table 2 presents the results of a number of such 
experiments. Each experiment involved duplicate flasks for each 
condition and the numbers presented here represent the mean of at 
least two such experiments. 
These results confirm the synergism between MTX and FUra when 
MTX precedes FUra. Combination of TAM and MTX is antagonistic at 
high and low doses, while sequential TAM-MTX is additive. The com¬ 
bination of 10yM TAM and FUra shows a synergistic interaction while 
sequential treatment is additive. When O.OlpM TAM is used, both 
sequential and combination treatment are antagonistic. Finally, 
the results show that sequential TAM-MF is a synergistic combination 
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high dose TAM, but additive with low dose TAM; simultaneous use of 
either high or low dose TAM with MF is antagonistic. 
Another experiment, performed using dialyzed serum, sought to 
compare directly the interaction of 10yM TAM with MTX,FUra and MF. 
For combined treatments, cells were seeded at 200,000 oer flask and 
corrections were made to calculate % control growth. Furthermore, be¬ 
cause treatments were begun at various times after seeding, each 
combination had its own ethanol and TAM controls. However, iden¬ 
tical antimetabolite treatments are performed at the same time. 
The results are presented in Table 3 (these results were also used 
in determining the values for Table 2). This experiment confirms 
the previous results in showing that sequential TAM-MF inhibits 
colony growth of 47-DN to a greater degree than combination TAM-MF. 
It also shows the superiority of combination TAM-FUra over sequential 
TAM-FUra in growth inhibition. These results finally show a sig¬ 
nificant difference between sequential TAM-MTX and the simultaneous 
combination of TAM-MTX. 
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Table 2 
- 
TAM-Antimetabol ite Interactions 
Mean % Growth + S.D. Mean ICE ± S.D. Interaction,p value* 
51.2 + 22 
130+58 
71.0 + 35 
44.0 + 15 
jd 5 14.5 + 13 0.48 + 0.4 synergistic,p<0.01 
MTX 0.5 35.7 + 14 1.73 + 1 antagonistic,p<0.05 
+ MTX 0.5 109+50 2.33 + 2 antagonistic,p<0.05 
X 0.5 32.8 + 30 1.08 + 0.4 additive,p>0.10 
MTX 0.5 110 + 11 1.21 + 0.1 additive,p>0.10 
FUra 5 16.5 + 7 0.49 + 11 synerqistic,p<0.01 
+ FUra 82.4 + 31 1.30 + 0.3 antagonistic,p<0.01 
ra 5 27.2 + 8 1.01 ± 0.3 additive,d>0.10 
FUra 5 41.4 + 6 1.32 + 0.2 antagonistic,p<0.05 
MF 18.6 + 10 11.2 + 11 antagonistic,p<0.01 
+ MF 18.2 + 6 5.68 + 5 antagonistic,p<0.01 
7.1 + 3 0.64 + 0.3 synerqistic,p<0.05 
-MF 25.4 + 10 0.79 + 0.3 additive,p>0.10 
— 
:i al 
ition 
►FUra (see text) *two-tailed t test for the null 
hypothesis, ICE = 1 
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Table 3 
TAM-Antimetabol i te Interactions in Dialyzed Serum 
Ratio % Growth in Drug treated/% Control growth* P* 
Combination Sequential 
i MTX 0.5 0.73 + 0.08 0.31 ± 0.15 p<0.01 
j FUra 5 0.28 + 0.005 0.68 + 0.19 p<0.01 
d MF 0.60 ± 0.07 0.25 ± 0.09 p<0.01 
atments consist of TAM-Antimetabolite treatments in either combination or 
al fashion; control growth is growth in TAM alone. 
ed t test for the null hypothesis: combination and sequential treatments 
equal growth. 
of TAM before MTX and before sequential MTX (M) and FUra (F) was superior to 
of TAM simultaneously with these drugs. TAM, however, resulted in the greatest 
of cells exposed to FUra when it was added with the FUra and not when it was 
■ior to FUra. 
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V. Discussion 
The dose response relationship obtained for TAM inhibition of clonal 
growth of the 47-DN human mammary tumor cell line indicates that these 
cells are sensitive to the growth inhibitory effects of this anti estrogen. 
The cells do contain estrogen receptors (11), but this does not necessarily 
imply TAM sensitivity (23). Estrogen receptor measurements have been 
made on this cell line under control conditions and after TAM treat¬ 
ment (10pM, 72 hours). The addition of TAM reduces cytoplasmic ER 5- 
fold and PgR 4-fold (46). These results indicate that TAM is altering 
the normal course of events in estrogen receptor processing and suggest 
that the growth inhibitory Droperties of TAM are mediated through the 
ER. Clinical studies have shown that TAM blood levels of 0.55yM are 
therapeutically effective (27), and in the 47-DN line continuous exDO- 
sure to this concentration of TAM does show some inhibition of colony 
growth. Blood levels greater than lpM are achievable clinically, and 
the in vitro data suggest that these levels would have greater ability 
to inhibit breast tumor growth. 
The apparent independence of the TAM sensitivity of 47-DN to insulin 
present in the medium shows the insulin-estrogen relationship of 47-DN 
to be different from that of MCF-7. Butler (22) has shown that the 
presence of insulin lowered ER and TAM sensitivity in MCF-7, but the 
presence of insulin had no effect on the sensitivity of 47-DN to TAM. 
Studies of these hormonal relationships in other mammary tumor systems 
have indicated several mechanisms depending on the tumor's response to 
insulin. In DMBA-induced mammary tumors which regress when the rats 
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are made diabetic, replacement of insulin leads to tumor growth and 
increased estrogen binding capacity (47). Insulin independent tumors 
behave in a manner similar to MCF-7, for the absence of insulin leads 
to an increased ER content. Furthermore, there exist some tumors which 
remain static under insulin deprivation, and the ER content is not 
affected by insulin addition or deprivation (48). The 47-DN cell 
line seems to fit most closely with this last model. 
While insulin does not appreciably affect the sensitivity of 47-DN 
to TAM, it has a marked influence on the cytotoxicity of FUra. The 
mechanism of insulin's enhancement of FUra cytotoxicity may possibly 
be understood by a consideration of insulin's modulation of biochemical 
pathways within the cell. In a previously mentioned study (13) 
involving insulin-dependent DMBA-induced mammary tumors in diabetic and 
intact rats, insulin deprivation leads to tumor regression accompanied 
by decreases in RNA levels, increases in DNA levels, and decreased 
activities of glycolytic enzymes and enzymes of the hexose-monophosphate 
pathway. While the TAM studies of 47-DN indicate that the cells may not 
be deoendent on insulin, they nevertheless may respond biochemically to 
the presence of insulin. Insulin definitely stimulates the hexose-mono¬ 
phosphate pathway in liver cells and adipocytes (49). The hexose-mono¬ 
phosphate pathway serves to generate reducing power in the form of NADPH, 
to convert hexoses to pentoses, and to complete oxidative deoradation 
of pentoses (50). The second function is important for this discussion, 
for the pentose formed, D-ribose-5-phosohate, is required in the synthe¬ 
sis of nucleic acids. PRPP is formed from D-ribose 5-phosDhate in one 
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step at the expense of ATP (49), and the role of PRPP in the toxicity 
of FUra is discussed above. The presence of insulin is therefore nec¬ 
essary for maximum formation of FUra nucleotides which may serve to 
inhibit DNA synthesis or become incorporated into RNA. In the absence 
of insulin, cells may have lower PRPP pools available for the metabolism 
of FUra which is necessary for its ability to inhibit growth of cells. 
The interaction of TAM and MTX in inhibitino the arowth of 47-DN 
~ 
is as expected. Pretreatment with TAM and rescue with fresh medium 
followed by MTX should be more cytotoxic than TAM pretreatment followed 
by MTX with no rescue. TAM inhibits DNA synthesis (17) and since MTX's 
lethal effects are dependent upon the cells' synthesizinq DNA (28), 
the two drugs should interact in an antagonistic manner if given 
together. Treatment and rescue might be expected to cause a certain dearee 
of synchronization of the tumor cells, which should enhance MTX toxicity 
(42). In fact flow cytometric studies show that TAM can produce a G-j 
or G-j-S block at growth inhibitory concentrations (46). Seguential 
treatment with 10yM TAM and MTX was superior to combination treatment, 
but true synergism was not seen with either low or high dose TAM. 
The interactions of TAM and FUra are consistent with the work 
of Benz and Cadman, in that 10pM TAM in combination with FUra is 
synergistic and superior to sequential therapy. The interaction 
of TAM and FUra may thus be highly dependent on TAM concentration 
because synergism is only observed with high doses and the low dose 
of TAM interacts antagonistically with FUra. If sequencing does 
result in synchronization of the cycling of the tumor cells, we would 
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not expect it necessarily to enhance the cytotoxicity of FUra. The 
lethal effects of FUra are not dependent on DNA synthesis (29), and 
synchronization with other agents has been shown not to affect the 
cytotoxicity of FUra (42). 
At least two mechanisms may be considered in an attempt to explain 
the interaction between TAM and FUra. Two groups of investigators 
have reported that RNA molecules are able to inhibit the binding of 
ER complexes to DNA (51,52) and suggest that steroid receptor com¬ 
plexes may participate in the regulation of RNA synthesis and post- 
transcriptional control (51). TAM-ER complexes could certainly 
lead to alteration of these normal regulatory and Drocessing steps. 
Part of the cytotoxicity of FUra may be due to its incorporation into 
RNA, with subsequent formation of "fraudulent" RNA, which may inter¬ 
fere with normal post-transcriptional processing (32). If at least 
2 separate steps in the RNA processing pathway were blocked or altered 
by the respective affects of TAM and FUra, synergistic interaction 
of the 2 drugs may occur and would involve "sequential" inhibition (53). 
These two drugs by interfering with the normal production of mature 
RNA by the cell would have resulting adverse affects on normal cellular 
protein synthesis and metabolism. 
Another model for the interaction of TAM and FUra involves a "com¬ 
plementary inhibition" model. Sartorelli described such a model for the 
interaction of agents which bind and inactivate macromolecules with 
drugs which alter biosynthetic pathways leading to formation of end- 
products which are either non-functional or only partially functional 
(54). The activities of TAM and FUra may easily be fit into such a 
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model,since TAM-ER complexes certainly interact with chromatin and 
or RNA molecules. As already mentioned, FUra may have ultimate effects 
on both DNA and RNA biosynthetic pathways. 
The interaction of TAM and MF treatment demonstrates the value TAM 
may have as a synchronizing agent in vitro. Pretreatment of 47-DN with 
1OyM TAM followed by estrogen rescue and MF administration inhibits 
colony growth to <10% of control at the doses used, and the ICE value 
clearly shows synergistic interaction. This synergism was not observed 
when low dose TAM (O.OlpM) was used in a similar manner. Synchronization 
of the tumor cells followed by release would be expected to enhance 
the toxicity of MF if MTX was given as a large proportion of the 
cells entered the S phase of the cell cycle together. MTX's ability 
to enhance FUra toxicity is dependent on the cells' synthesizina 
DNA and thus nucleotides, so that tetrahydrofolic acid pools may 
be depleted as a result of the MTX-block of dihydrofolate reductase 
(Fig. 4). When cells are not rescued from the inhibition Droduced 
by TAM, the combined effects of TAM and MF are antagonistic. This 
is to be expected, for TAM prevents DNA synthesis, which is necessary 
for maximum growth inhibition to occur upon administation of MF 
in the manner described above. 
These findings have great importance in the design of rational 
schedules of treatment of breast cancer. Gewirtz and Cadman have 
shown the efficacy of MF in the treatment of advanced breast cancer. 
We now have information on effective ways of adding TAM, already 
widely used in the treatment of breast cancer, to this antimeta¬ 
bolite combination in the treatment of individuals whose tumors 
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have been shown to contain ER. TAM should not be given concurrently 
with MF, as in the study of Huba.y et al_. (34), but should rather 
be administered before MF treatment, in a manner similar to the 
protocol of Alleqra et aj_. (35). TAM should not enhance the tox¬ 
icity of MF to any cells of the hosts which do not contain ER. 
Because only a limited number of estrogen target oraans exist 
in the body and do not include common sites of antimetabolite tox¬ 
icity, the use of TAM should not significantly increase chemother¬ 
apeutic toxicity. The combination of its intrinsic growth in¬ 
hibition of mammary tumors, its ability to enhance MF tumoricidal 
action, and its low host toxicity suggest that its appropriate in¬ 
clusion in the chemo-hormonal therapy of breast cancer should 
yield protocols that give a highly favorably therapeutic index 
in the treatment of this significant disease. 
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